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OBJECTIVE: The purpose of the study was to assess cost-
effectiveness of novel DMARDs for RA therapy from the
managed care perspective. METHODS: Utilizing a claims
database, RA patients initiated on various dose regimens
of leﬂunomide (LEF), etanercept (ETA) and inﬂiximab
(INF) in 1999 or 2000 were followed for 12 months post
drug index date and mean RA-related direct medical
charges were calculated for each study cohort. Twelve-
month estimates of the American College of Rheumatol-
ogy response criteria (ACR 20) and mean change in the
Health Assessment Questionnaire Disability Index (HAQ
DI) were used as effectiveness measures from published
clinical trials. Average (CE) and incremental cost-
effectiveness (ICER) ratios were calculated and one-way
sensitivity analyses were performed. RESULTS: Mean
RA-related direct medical charges (95% CI) for LEF, ETA
and INF for 1-year of therapy post-index date were
$16,107 (14654, 17856), $25,550 (24251, 26711) and
$55,195 (49928, 60305). Twelve-month ACR 20 esti-
mates were 52%, 72% and 42% and mean changes in
HAQ DI were -0.45, -0.62 and -0.29, respectively. The
LEF CE [ACR 20] was $30,976 compared to $35,486
(ETA) and $131,417 (INF) while LEF CE [HAQ DI] 
was $35,794 compared to $41,210 (ETA) and $190,329
(INF). Sensitivity analyses of key parameters: cost,
ACR20, HAQDI did not inﬂuence the rank order of
results. Worst-case estimates for LEF [ACR 20 = 0.51;
HAQ DI = -0.41] resulted in a CE of $31,583 and
$39,286, which was lower than the base-case CE of ETA
and INF. The ICER for ETA vs. LEF was $47,213 [ACR
20] and $55,544 [HAQ DI]. Both LEF and ETA domi-
nated INF. CONCLUSION: Evidence from the economic
analysis demonstrates that LEF is a cost-effective alter-
native among novel DMARDs for RA patients in a
managed care setting.
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OBJECTIVES: Rheumatoid arthritis (RA) affects 1% of
adults in the developed world, impacting on functional
activities and life expectancy. The burden of RA is sig-
niﬁcant, with substantial direct medical costs and indirect
costs, such as time off work and exclusion from the work-
force. Treatments include medication, functional rehabil-
itation and surgery. The objective was to assess the
hospital resource use and costs for treating RA in France,
from a health insurance perspective. METHODS: Using
the national hospital activity database, PMSI, patients
with either a primary, secondary or related RA diagnosis
were identiﬁed and their hospital care analysed. PMSI
data covers almost all public and private hospitals in
France, providing Health Authorities with activity 
indicators for budget allocations. RA admissions were
selected by ICD-10 codes M05 and M06 and analysed by
primary, secondary and related RA diagnoses. Hospital
activity captured included procedures undertaken and
occupied bed days, and was separated into public and
private hospital activity. Comorbidities and DRGs 
represented were also identiﬁed. RESULTS: In 2000,
51,985 admissions were related to RA. Public hospitals
accounted for 75% of admissions; 74% were women.
Procedures were performed in 70% of admissions, with
an average of 3.6 per admission. Of these, 3,118 were
RA-related joint procedures. The mean length of stay was
6.4 days +/-10.1, corresponding to 329,098 occupied 
bed days. Twenty-four percent of bed days were due to
primary RA and 71% to secondary RA. Main DRGs were
341 and 340 (connective tissue diseases), 808 (diseases of
the musculoskeletal system and connective tissue, ambu-
latory treated) and 295 (major intervention on joint
replacement), which accounted for 83% of primary RA
admissions and cost €31 million (80% of primary RA
cost). CONCLUSIONS: The burden of RA is signiﬁcant
in the French healthcare system, with high hospital
resource use, including costly joint replacement 
procedures.
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